Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 7/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.62 |
| ▸ | ESR1 | P03372 | 10/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13948726 | 0.89 | ESRRA (0.60) | ESRRAESR2ESR1 | |
| SCHEMBL2584462 | 0.82 | ESRRA (1.00) | ESRRAESR2ESR1 | |
| SCHEMBL2591941 | 0.77 | ESR2 (0.68) | ESRRAESR2ESR1 | |
| SCHEMBL2584478 | 0.77 | ESR1 (1.00) | ESRRAESR2ESR1 | |
| SCHEMBL2592361 | 0.77 | ESR1 (0.68) | ESRRAESR2ESR1 | |
| SCHEMBL15030856 | 0.77 | ESR1 (0.68) | ESRRAESR2ESR1 | |
| SCHEMBL2588204 | 0.76 | ESRRA (0.61) | ESRRAESR2 | |
| SCHEMBL14916041 | 0.76 | ESR1 (0.86) | ESRRAESR2ESR1 | |
| SCHEMBL2592860 | 0.74 | ESR2 (1.00) | ESRRAESR2ESR1 | |
| SCHEMBL2582077 | 0.74 | ESR2 (0.73) | ESRRAESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2017-01-19 | — | — | US | claimed |
| CN-103432133-A | Use of nuclear receptor binding agents | GTX INC | 2013-12-11 | — | — | CN | claimed |
| EP-2647376-A1 | Nuclear receptor binding agents | Gtx, Inc. (US) | 2013-10-09 | — | — | EP | claimed |
| CN-101641013-A | Nuclear receptor binding agents | GTX INC US | 2010-02-03 | — | — | CN | claimed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | claimed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9623021-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9604931-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| CN-106420745-A | Application of nuclear receptor binding agents in preparation of drugs for treating obesity, fibrosis, and cardiovascular diseases | GTX公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-102970870-A | Nuclear receptor binding agents | GTX INC | 2013-03-13 | — | — | CN | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2010-10-21 | — | — | US | disclosed |
| CN-101641013-A | Nuclear receptor binding agents | GTX INC US | 2010-02-03 | — | — | CN | disclosed |
| EP-2106212-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, Inc. (US) | 2009-10-07 | — | — | EP | disclosed |
| US-20090030036-A1 | Nuclear receptor binding agents | GTX, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008091555-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170014401-A1 | NUCLEAR RECEPTOR BINDING AGENTS | ESRRB, ESRRG, ESRRA | ESRRA 3/4885ESR2 4/4885ESR1 28/4885 |
| US-20090030036-A1 | Nuclear receptor binding agents | NR0B1, NR2E3, NR0B2 | ESRRA 4/4885ESR2 22/4885ESR1 63/4885 |
| US-20100267767-A1 | NUCLEAR RECEPTOR BINDING AGENTS | FABP1, FABP4, ADIPOR2 | ESRRA 11/4885ESR2 16/4885ESR1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.